Company: GMRE
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001104659-25-110926
Chunk: 49

Company: Global Medical REIT Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 49
---
 Consequently, no key information document required
by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the EUWA (the “UK PRIIPs Regulation”) for offering
or selling the shares of Series B Preferred Stock or otherwise making them available to retail investors in the UK has been prepared
and therefore offering or selling the shares of Series B Preferred Stock or otherwise making them available to any retail investor
in the UK may be unlawful under the UK PRIIPs Regulation.

<div align='center'>S-28

LEGAL MATTERS</div>

Certain legal matters will be passed upon for
us by Vinson & Elkins L.L.P., Richmond, Virginia, and, with respect to matters of Maryland law, by Venable LLP, Baltimore, Maryland.
Certain legal matters will be passed upon for the underwriters by Cooley LLP, New York, New York.

<div align='center'>EXPERTS</div>

The financial statements of Global Medical REIT Inc. and the related
financial statement schedule as of December 31, 2024 and 2023, and for each of the three years in the period ended December 31, 2024,
incorporated by reference in this Prospectus by reference to Global Medical REIT Inc.’s annual report on Form 10-K for the year ended December 31, 2024, and the effectiveness of the Global Medical REIT Inc.’s internal control over financial reporting have
been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their reports. Such financial
statements and related financial statement schedule are incorporated by reference in reliance upon the reports from such firm given their
authority as experts in accounting and auditing.

<div align='center'>S-29</div>

PROSPECTUS

<div align='center'>$750,000,000

Common Stock
Preferred Stock
Debt Securities</div>

We may offer, issue and sell from time to time,
together or separately, the securities described in this prospectus, at an aggregate public offering price that will not exceed $750,000,000.

We will provide the specific terms of any securities
we may offer in supplements to this prospectus. You should read this prospectus and any applicable prospectus supplement carefully before
you invest. This prospectus may not be used to offer and sell any securities unless accompanied by a prospectus supplement describing
the amount of and terms of the offering of those securities